Drug Trial Radar · NCT06235099
Copper Cu 64 PSMA I&T PET Imaging in Men With Suspected Recurrence of Prostate Cancer
Last checked: Nov 20, 2026Latest source record: Feb 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
235
Actual
Start
Apr 1, 2024
Primary completion
Feb 18, 2025
Study completion Feb 18, 2025
Sponsor
- Lead sponsor
- Curium US LLCIndustry
- Sponsor type
- Industry
- First posted
- Jan 31, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective, open-label Phase 3 study to evaluate copper Cu 64 PSMA I\&T injection for PET/CT imaging in patients with recurrent prostate cancer after radical prostatectomy or radiation therapy.
Conditions
- Prostate Cancer
- Prostate Adenocarcinoma
- Biochemical Recurrence of Malignant Neoplasm of Prostate
Interventions
Copper Cu 64 PSMA I&TDrug
Radiopharmaceutical PET imaging tracer injected intravenously for the detection of PSMA expression.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Patient-Level Correct Detection Rate (CDR)Time frame: 4 hours
- Region-Level Correct Localization Rate (CLR)Time frame: 4 hours
Locations
31 sites in 1 country. Site status is shown where the registry gives one.
Providence Medical Foundation
Fullerton, California
Tower Urology
Los Angeles, California
VA Greater Los Angeles Healthcare System
Los Angeles, California
Hoag Memorial Hospital Presbyterian
Newport Beach, California
University of California, Irvine
Orange, California
San Francisco VA Medical Center
San Francisco, California
Providence Saint John's Health Center
Santa Monica, California
Stanford Hospital & Clinics
Stanford, California
Georgetown University Medical Center
Washington D.C., District of Columbia
University of Miami Miller School of Medicine
Miami, Florida
Biogenix Molecular, LLC
Miami, Florida
Florida Urology Partners
Tampa, Florida
Edward Hines Jr VA Hospital
Hines, Illinois
Urology of Indiana, LLC
Carmel, Indiana
Indiana University Health Neuroscience Center
Indianapolis, Indiana
University of Iowa
Iowa City, Iowa
The University of Kansas Hospital
Kansas City, Kansas
M Health Fairview University of Minnesota Medical Center
Minneapolis, Minnesota
SSM Health Saint Louis University Hospital
St Louis, Missouri
John Cochran VA Medical Center
St Louis, Missouri
Washington University School of Medicine
St Louis, Missouri
Great Plains Health, Diagnostic Imaging
North Platte, Nebraska
XCancer
Omaha, Nebraska
Queens Hospital Center
Jamaica, New York
James J. Peters VA Medical Center
The Bronx, New York
Cleveland Clinic
Cleveland, Ohio
VA Portland Health Care System
Portland, Oregon
Carolina Urologic Research Center, LLC
Myrtle Beach, South Carolina
University of Tennessee Medical Center
Knoxville, Tennessee
Excel Diagnostics and Nuclear Oncology Center
Houston, Texas
Urology San Antonio
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.